Eli Lilly & Co. (LLY) Announces Presentation of Positive Data from ALIMTA + KEYTRUDA Study in NSCLC (MRK)
Tweet Send to a Friend
Important clinical study results from one of Eli Lilly and Company's (NYSE: LLY) ongoing immuno-oncology collaborations with Merck (known as ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
